advertisement

---

Shimizu K 11

Showing records 1 to 11 | Display all abstracts from Shimizu K

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Inoue K
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Inoue K; Shiokawa M
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Shiokawa M
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Kunimatsu-Sanuki S
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Katakura S
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Nozaki N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tsuruoka M; Kunimatsu-Sanuki S
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Shimizu K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Shimizu K
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Ishida K; Tomita G
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Ishida K; Tomita G
American Journal of Ophthalmology 2022; 237: 114-121

---